Get started
Author

Toshko Jelev Lissitchkov

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
2017 · K. John Pasi, Savita Rangarajan, et al. · New England Journal of Medicine · 375
PDF
Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors
2007 · B.A. KONKLE, L.S. EBBESEN, et al. · Journal of Thrombosis and Haemostasis · 330
PDF
Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial
2016 · Elena Santagostino, Uri Martinowitz, et al. · Blood · 229
PDF
Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)
2013 · M.J. Manco-Johnson, C.L. Kempton, et al. · Journal of Thrombosis and Haemostasis · 201
PDF
Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort
2021 · K. John Pasi, Toshko Lissitchkov, et al. · Journal of Thrombosis and Haemostasis · 111
PDF
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial
2012 · Wolfgang U. Knauf, Toshko Lissitchkov, et al. · British Journal of Haematology · 110
PDF
Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy
2005 · T. Lissitchkov, G. Arnaudov, et al. · Journal of Cancer Research and Clinical Oncology · 79
Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study
2021 · Toshko Lissitchkov, Annemieke Willemze, et al. · Blood Advances · 55
PDF
PK ‐guided personalized prophylaxis with Nuwiq® (human‐cl rh FVIII ) in adults with severe haemophilia A
2017 · T. Lissitchkov, L. Rusen, et al. · Haemophilia · 54
PDF
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B
2013 · J. Windyga, T. Lissitchkov, et al. · Haemophilia · 49
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma
2004 · S. Rao, D. Watkins, et al. · Annals of Oncology · 48
PDF
Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
2020 · Maria Elisa Mancuso, Aaron Lubetsky, et al. · Journal of Thrombosis and Haemostasis · 47
PDF
Results of a phase I/II open‐label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients
2015 · U. Martinowitz, T. Lissitchkov, et al. · Haemophilia · 42
PDF
Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq ® ) in adults with severe haemophilia A: efficacy and safety
2015 · T. Lissitchkov, K. Hampton, et al. · Haemophilia · 41
PDF
Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency
2017 · C. Ross, S. Rangarajan, et al. · Journal of Thrombosis and Haemostasis · 38
PDF
Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A
2016 · Anita Shah, Alexander Solms, et al. · Clinical Pharmacokinetics · 37
PDF
Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq ® (human‐cl rh FVIII ) in previously treated patients with severe haemophilia A
2018 · Y. Dargaud, C. Negrier, et al. · Haemophilia · 35
Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rh FVIII ) in adults with severe haemophilia A
2015 · A. Tiede, J. Oldenburg, et al. · Haemophilia · 35
Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients
2019 · Toshko Lissitchkov, Bella Madan, et al. · Journal of Thrombosis and Haemostasis · 33
PDF
Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B
2024 · Steven W. Pipe, Toshko Lissitchkov, et al. · Blood Advances · 30
Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
2020 · Alexander Solms, Anita Shah, et al. · Annals of Hematology · 30
PDF
Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
2019 · Anita Shah, Alexander Solms, et al. · Annals of Hematology · 30
PDF
In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer—changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-γ lymphokine profile
2001 · M. Mincheff, I. Altankova, et al. · Critical Reviews in Oncology/Hematology · 30
Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
2023 · Toshko Lissitchkov, Annemieke Willemze, et al. · Research and Practice in Thrombosis and Haemostasis · 29
PDF
Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program
2019 · Toshko Lissitchkov, Anna Klukowska, et al. · Therapeutic Advances in Hematology · 28
PDF
Works count: 94
Citation count: 2,663
H-index: 27
I10-index: 52
Year
Topic
Type